ARPO
Aerpio Pharmaceuticals Inc
A clinical-stage biopharmaceutical company that develops medicines for vascular and eye diseases, working on therapies that target the Tie2 pathway to treat conditions like diabetic macular edema and glaucoma. It came out of Akebia Therapeutics as a spinoff focused on vascular biology, with its name rooted in the vessel-related research at its core. Its lead experimental drug, AKB-9778, was developed to help keep blood vessels in the eye healthy and stable.
CUSIP: 00810B105HealthcareUS1 holder
Total Value
$1.29M
Total Shares
1.00M
Net Share Change
+1.00M
Activity
1 buying
Investor
Value
Shares
Weight
Change
